GLP-1 - IMSDA

India Pharma Knowledge Roundup June 2026: Women’s Health, Semaglutide Boom and Quality Reform

Post published:June 22, 2026
Post category:Knowledge

June 2026 marks a pivotal moment for India's generic pharmaceutical industry. From landmark shifts toward women's health therapeutics to explosive growth in the generic GLP-1 market and sweeping drug-quality reforms,…

India’s Generic Semaglutide Boom Reshapes Global GLP-1 Market

Post published:June 15, 2026
Post category:News

Indian generic drugmakers have launched a wave of affordable semaglutide products following the expiry of Novo Nordisk's key patents, with over 50 brands expected in the coming months and prices…

India’s Semaglutide Generic Boom Reshapes GLP-1 Market in 2026

Post published:June 5, 2026
Post category:News

On March 20, 2026, Novo Nordisk's patent on semaglutide expired in India, triggering one of the most significant transformations in the country's pharmaceutical history. Within weeks, more than 40 Indian…

India’s Generic Drug Resilience: 20% Global Market Share, US Tariff Exemption, and the Semaglutide Revolution

Post published:May 22, 2026
Post category:News

India's pharmaceutical industry continues to demonstrate remarkable resilience and global influence in 2026. With the nation supplying approximately 20% of the world's generic medicines, recent developments — including US tariff…